The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2022 | Updates in colorectal cancer research from ESMO WCGIC 2022
Erika Martinelli, MD, PhD, University of Campania Luigi Vanvitelli, Caserta, Italy, discusses some of the highlights in colorectal cancer (CRC) research from ESMO WCGIC 2022. Dr Martinelli comments on updates in the use of anti-vascular endothelial growth factor (VEGF) receptor therapy for the treatment of CRC. Moreover, Dr Martinelli discusses the Phase II MOUNTAINEER trial (NCT03043313) in which tucatinib (a HER-2 inhibitor) in combination with trastuzumab showed high efficacy for the treatment of refractory CRC. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
